Michael Egholm - 22 May 2025 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Reporting relationship: President & CEO, Director
Issuer ticker: LAB
Reported as of: 22 May 2025
Net transaction value: -$5,126
SEC form: 4
Accepted by SEC: 27 May 2025, 20:28:33 UTC
Prior SEC filing: 22 May 2025
Next SEC filing: 28 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Michael Egholm by Tomone Tanaka, Attorney-in-Fact

Key filing fact

Michael Egholm filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 27 May 2025.

Key facts

This page summarizes Michael Egholm's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 May 2025, 20:28.

Change

Previous filing in this sequence was filed on 22 May 2025.
Current net transaction value: -$5,126.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001559779 Primary reporting owner

Egholm Michael

Relationship: President & CEO, Director
Address: C/O STANDARD BIOTOOLS INC., 2 TOWER PLACE, STE 2000, SOUTH SAN FRANCISCO
Signature: /s/ Michael Egholm by Tomone Tanaka, Attorney-in-Fact
Signature date: 27 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LAB transaction

Common Stock

Sale

Transaction value: $5,126
Shares: -5,116
Change %: -0.19%
Price: $1.00
Shares after: 2,746,664
Date: 22 May 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares were sold to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission ("SEC") on March 24, 2025.

Footnote F2

Represents the weighted average sales price per share. The shares sold at prices ranging from $0.9403 to $1.03 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.